2. Academic Validation
  3. Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase

Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase

  • Sci Rep. 2023 Jul 31;13(1):12397. doi: 10.1038/s41598-023-39424-8.
Faeze Yousefnejad 1,  Mahyar Mohammadi-Moghadam-Goozali 2,  Mohammad Hosein Sayahi 3,  Mohammad Halimi 4,  Ali Moazzam 1,  Maryam Mohammadi-Khanaposhtani 5,  Somayeh Mojtabavi 6,  Mehdi Asadi 7,  Mohammad Ali Faramarzi 6,  Bagher Larijani 1,  Massoud Amanlou 8,  Mohammad Mahdavi 9
Affiliations

Affiliations

  • 1 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • 2 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • 3 Department of Chemistry, Payame Noor University, P.O. Box 19395-3697, Tehran, Iran.
  • 4 Department of Biology, Islamic Azad University, Babol Branch, Babol, Iran.
  • 5 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
  • 6 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • 7 Department of Medicinal Chemistry, Faculty of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
  • 8 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. amanlou@tums.ac.ir.
  • 9 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. momahdavi@tums.ac.ir.
PMID: 37524733 DOI: 10.1038/s41598-023-39424-8
Abstract

α-Glucosidase as a carbohydrate-hydrolase Enzyme is a crucial therapeutic target for type 2 diabetes. In this work, benzo[d]imidazole-amide containing 1,2,3-triazole-N-arylacetamide derivatives 8a-n were synthesized and evaluated for their inhibitory activity against α-glucosidase. In vitro α-glucosidase inhibition assay demonstrated that more than half of the title compounds with IC50 values in the range of 49.0-668.5 μM were more potent than standard inhibitor acarbose (IC50 = 750.0 µM). The most promising inhibitor was N-2-methylphenylacetamid derivative 8c. Kinetic study revealed that compound 8c (Ki = 40.0 µM) is a competitive inhibitor against α-glucosidase. Significantly, molecular docking and molecular dynamics studies on the most potent compound showed that this compound with a proper binding energy interacted with important Amino acids of the α-glucosidase active site. Study on cytotoxicity of the most potent compounds 8c, 8e, and 8g demonstrated that these compounds did not show cytotoxic activity against the Cancer and normal cell lines MCF-7 and HDF, respectively. Furthermore, the ADMET study predicted that compound 8c is likely to be orally active and non-cytotoxic.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z